New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.
Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer s Disease, Insomnia and Epilepsy
Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer s disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company s deep neurology pipeline and portfolio, including Alzheimer s disease, insomnia and epilepsy, will be presented at the 73
rd Annual Meeting of the American Academy of Neurology (AAN), taking place virtually from April 17-22, 2021.